Summary of DURATION development program select efficacy results: absolute difference in change in A1C, body weight, systolic blood pressure, and LDL cholesterol.

Slides:

Advertisements

Similar presentations

Pancreas, Insulin & Diabetes In One Day 2015.

Advertisements

Non-diabetes 64.7% Diabetes 35.3% Diagnosed diabetes 5.6% Pre-diabetes 26.0% Undiagnosed diabetes 2.8% Age-adjusted diabetes prevalence among Alaska adults,

Diabetes and High Blood Pressure Are Like Twins. Ignoring Your High Blood Pressure.

PICK A CARD When the picture you hold in your hand is displayed you will be asked a question Ready set go…….

Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea A.

PICK A CARD The wheel will spin and whoever has that card will be asked a question about the subject pictured on the card Ready set go…….

Lacto-ovo vegetarian group

Circ Cardiovasc Qual Outcomes

Association of low eosinophil and lymphocyte counts with different initial presentations of cardiovascular disease over the first 6 months ‘Low eosinophils’

Relative mortality risk associated with quartiles of systolic blood pressure compared with systolic

Change (with 95% CI) in outcomes by duration of type 2 diabetes

Cholesterol and blood pressure values at baseline and after 15 days of dark-chocolate and white-chocolate consumption Characteristic Dark chocolate before.

Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.

Sodium-glucose co-transporter 2 (SGLT2) inhibitors work by blocking the reabsorption of filtered glucose in the kidneys. This leads to glucosuria and improved.

Rank-order bar chart of percentage of patient-days with blood glucose results > 299 mg/dl for non-ICU units. Rank-order bar chart of percentage of patient-days.

Figure 5 Risk factor control in the intensive treatment group

Joshua A. Bell et al. JACC 2018;72:

A summary of Lisa and Gerard, the two personas created during this study, including quotes that describe their attitude toward diabetes. A summary of Lisa.

PWD confidence with key diabetes management activities.

PWD who regularly or occasionally engaged in activities to manage their diabetes. PWD who regularly or occasionally engaged in activities to manage their.

Description of studies for pooled analyses

The means and SDs of the data from all Glucommander runs from 1984 to 1998 are graphed. The means and SDs of the data from all Glucommander runs from 1984.

Impact of U-100 RHI administered with V-Go at OV1 (3 months after initiation) and OV2 (6 months after initiation) (n = 11) at 3 months (P = 0.32) and at.

Changes in A1C (A), body weight (B), and systolic blood pressure (C) with canagliflozin in combination with incretin-based therapies. *In the dose-advancement.

Level of risk factor control in the overall sample and by gender

Screening, enrollment, and randomization of study participants (BMI, body mass index; CTG, conventional therapy group; HbA1c, glycated hemoglobin; HDL-C,

NAFLD (nonalcoholic fatty liver disease), CVD, and type 2 diabetes: Details of the study design Targher G et al. Diabetes Care 2007;30:

Baseline characteristics of CACTI type 1 diabetic subjects with cystatin C measurements (n=509), stratified by CAC progression status Maahs DM et al.

Ratio of relative risks of heart disease and stroke associated with higher blood pressure, smoking, type I and II diabetes, and higher cholesterol in women.

Reasons patients were excluded from the switch from atorvastatin to simvastatin J. A. Usher-Smith, et al. Int J Clin Pract 2007; 61:15–23.

Changes in weight and body mass index (BMI) associated with quality improvement. Changes in weight and body mass index (BMI) associated with quality improvement.

Baseline Characteristics, Blood Pressures, and Laboratory Values

Baseline Characteristics of the Subjects*

Disposition of Patients in the Atherogenic Dyslipidemia Study

(A) Low-density lipoprotein-cholesterol (LDL-C) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (A) Low-density.

Range of mean changes from baseline in A1C in clinical studies of 24–52 weeks’ duration reported in prescribing information for five GLP-1 receptor agonists.

Change in (A) total cholesterol; (B) LDL-cholesterol; (C) HDL-cholesterol and (D) triglycerides over 5 years in response to 12-week intensive lifestyle.

Demographic and Clinical Characteristics (means ± SD or %) of Subjects in Different Office SBP and DBP Categories Mancia G et al Hypertension. 2005;45:1072.

Change in %A1C over 5 years in response to 12-week intensive lifestyle intervention used in a real-world clinical practice. Change in %A1C over 5 years.

Range of mean changes from baseline in body weight in clinical studies of 24–52 weeks’ duration reported in prescribing information for five GLP-1 receptor.

RECORD Study: Enrollment and Outcomes

Relative risk of a major coronary heart disease event (myocardial infarction incidence, fatal coronary heart disease, or coronary revascularization) for.

Lars E. Laugsand et al. BTS 2016;j.jacbts

Change in (A) systolic blood pressure and (B) diastolic blood pressure over 5 years in response to 12-week intensive lifestyle intervention in a real-world.

Forest plot of CIMT progression rate for atorvastatin treatment versus placebo for 3 years by baseline serum 25-hydroxyvitamin D status. Forest plot of.

Relationship between selected metabolic parameters and the primary composite end point. Relationship between selected metabolic parameters and the primary.

Change in markers of glycometabolism and cardiovascular risk profile.

Percentage of patients with type 2 diabetes with A1C < 7% (n = 248), blood pressure > 130/80 mmHg (n = 248), and LDL cholesterol < 100 mg/dl (n = 207)

Mean (SD) weekly hemoglobin level (g/dl) and mean (SD) weekly epoetin dose by body weight (U/kg per week) were similar between epoetin alfa-epbx and epoetin.

Percentage of Florida adults with diagnosed diabetes who received services or engaged in self-management practices by DSME duration category, Florida BRFSS.

Mean LOS and 30-day all-cause readmission rates before and after conversion to the Interdisciplinary Diabetes Care model. Mean LOS and 30-day all-cause.

Associations of body mass index (BMI) levels with achieving targets for glycated hemoglobin (HbA1c), blood pressure (BP), and lipids in the upper panels.

Dimensions indexed to body surface area (AGA, appropriate birth weight for gestational age; SGA, small for gestational age; LVED, left ventricular end-diastolic;

Relationship between week 24 A1C and week 24 BeAM in the exploratory analysis (A), the main analysis (only patients with A1C >7.0% at week 24 were included.

Effect of empagliflozin on efficacy parameters at week 18.

Mean adjusted levels in each group for the following cardiometabolic risk factors at 3 and 12 months postpartum: (A) systolic blood pressure, (B) diastolic.

ORs of receiving metformin for outcome measures, including age, number of comorbidities, provider age, A1C level, history of CHF, and use of medications,

Glycemic control and body weight over 52 weeks.

Number of antihypertensive agents prescribed for known nephropaths in phases I and II (▪), with blood pressure recordings falling outside guidelines, compared.

ROC curves for cardiovascular events, all-cause mortality, and disease progression. ROC curves for cardiovascular events, all-cause mortality, and disease.

(D) Systolic blood pressure (BP) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. . (D) Systolic blood pressure.

Mean changes (standard error) from baseline in A1C (A and B) and body weight (C and D) for patients with type 1 (A and C) or type 2 (B and D) diabetes.

Hazard ratios, with 95% confidence intervals as floating absolute risks, as estimate of association between category of updated mean haemoglobin A1c concentration.

Pathway to initial antihypertensive therapy in patients with diabetes

Relationship between updated systolic blood pressure (SBP), right, and updated HbA1c, left, and the incidence of microvascular complications (closed symbols)

HR for mortality in ischemic heart disease.

HR for myocardial infarction.

Changes of major clinical and biochemical characteristics at baseline and during follow-up in different groups. Changes of major clinical and biochemical.

Adjusted HRs for death from any cause and death from specific causes among patients with type 1 diabetes. Adjusted HRs for death from any cause and death.

Benchmarking scatterplot for non-ICU units.

Presentation transcript:

Summary of DURATION development program select efficacy results: absolute difference in change in A1C, body weight, systolic blood pressure, and LDL cholesterol between exenatide once weekly and comparators. Summary of DURATION development program select efficacy results: absolute difference in change in A1C, body weight, systolic blood pressure, and LDL cholesterol between exenatide once weekly and comparators. Susan LaRue et al. Diabetes Spectr 2013;26:46-52 ©2013 by American Diabetes Association